{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408892547
| IUPAC_name = 4-amino-''N''-pyrimidin- 2-yl-benzenesulfonamide
| image = Sulfadiazine-2D-skeletal.png
| width = 250
| image2 = Sulfadiazine-3D-vdW.png
| width2 = 250
<!--Clinical data-->
| tradename =  
| class = [[Antibiotic|Antibiotic]] ([[Sulfonamide_(medicine)|sulfonamide]])<ref name=AHFS2016/>
| Drugs.com = {{drugs.com|monograph|sulfadiazine}}
| MedlinePlus = a682130
| pregnancy_US = C<ref name="pregnancy">{{cite web|title=Sulfadiazine Use During Pregnancy {{!}} Drugs.com|url=https://www.drugs.com/pregnancy/sulfadiazine.html|website=www.drugs.com|accessdate=28 June 2017|deadurl=no|archiveurl=https://web.archive.org/web/20161220222638/https://www.drugs.com/pregnancy/sulfadiazine.html|archivedate=20 December 2016|df=}}</ref>
| legal_status = 仅作为处方药
| routes_of_administration = 口服
<!--Pharmacokinetic data-->
| bioavailability = ?
| protein_bound = 38-48%<ref name="drugs.com">{{cite web|title=Sulfadiazine Monograph for Professionals {{!}} Drugs.com|url=https://www.drugs.com/monograph/sulfadiazine.html|website=www.drugs.com|accessdate=28 June 2017|5=|deadurl=no|archiveurl=https://web.archive.org/web/20161220223703/https://www.drugs.com/monograph/sulfadiazine.html|archivedate=20 December 2016|df=}}</ref>
| metabolism = 在[[肝脏|肝脏]]中[[乙酰化|乙酰化]]<ref name = "drugs.com" />
| elimination_half-life = 7-17小时 <ref name = "drugs.com" />
| excretion =经肾<ref name = "drugs.com" />
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 68-35-9
| ATC_prefix = J01
| ATC_suffix = EC02
| ATC_supplemental = {{ATCvet|J01|EQ10}}
| PubChem = 5215
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00359
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5026
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0N7609K889
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00587
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 439
<!--Chemical data-->
| C=10 | H=10 | N=4 | O=2 | S=1
| molecular_weight = 250.278 g/mol
| melting_point     = 252
| melting_high      = 256
}}
'''磺胺嘧啶'''（Sulfadiazine，可缩写为SD<ref name=Zhu2012>{{cite book|author1=朱依谆|author2=etal|title=药理学|edition=第7版|location=北京|publisher=人民卫生出版社|pages=478-481|ISBN=978-7-117-14403-2}}</ref>）是一种[[磺胺类药物|磺胺类抗菌药]]。磺胺嘧啶属于广谱抗菌药，对多数的[[革兰氏阳性菌|革兰氏阳性菌]]和[[革兰氏阴性菌|革兰氏阴性菌]]均有效，可用于全身感染的治疗<ref name=Zhu2012/><ref name=You2012>{{cite book|author1=尤启冬|author2=etal|year=2012|title=药物化学|edition=第7版|location=北京|publisher=人民卫生出版社|pages=350-355|ISBN=978-7-117-14434-6}}</ref>。磺胺嘧啶最早于1941年在美国得到上市批准<ref name=AHFS2016>{{cite web|title=Sulfadiazine|url=https://www.drugs.com/monograph/sulfadiazine.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161220223703/https://www.drugs.com/monograph/sulfadiazine.html|archivedate=20 December 2016|df=}}</ref>，属于[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]中的药物之一，在发展中国家，磺胺嘧啶的治疗费用大约每月是2.70至7.32美元，然而在美国使用磺胺嘧啶治疗的费用则可每月超过200美元。<ref name=ERC2014>{{cite web|title=Sulfadiazine|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=739&searchYear=2014|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref><ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=104}}</ref>

==特性==
磺胺嘧啶纯品为无臭无味的白色结晶或粉末状，在光照射下不稳定，粉末会逐渐变暗。磺胺嘧啶与硝酸银反应可生成外用药[[磺胺嘧啶银|磺胺嘧啶银]]，用于治疗[[烧伤|烧伤]]等引起的细菌感染<ref name=You2012/><ref name=Finch2010/>{{rp|337-340}}。

磺胺嘧啶口服易吸收，但吸收速度较慢，血药浓度在给药后3-6小时方达到高峰，半衰期则大约是17小时。磺胺嘧啶目前在磺胺类药物中拥有最低的血浆蛋白结合率和最高的[[血脑屏障|血脑屏障]]透过率。代谢方面，磺胺嘧啶会在肝脏内发生代谢，生成半衰期更长、无抗菌活性的乙酰化产物。磺胺嘧啶和代谢产生的乙酰化产物都主要通过[[肾小球|肾小球]]滤过清除。因为磺胺嘧啶水溶性低，可能会在[[尿|尿]]中形成结晶，对肾脏产生损害。可服用与磺胺嘧啶等量的碳酸氢钠使尿液碱化、增加磺胺嘧啶溶解度、减少结晶尿对肾脏的损伤<ref name=Zhu2012/><ref name=Finch2010/>{{rp|337-340}}。

==临床==
磺胺嘧啶可用于治疗全身性的感染，适用症包括[[风湿热|风湿热]]、[[软性下疳|软性下疳]]、[[披衣菌感染|披衣菌感染]]，以及[[流感嗜血杆菌|流感嗜血杆菌]]引发的感染<ref name=AHFS2016>{{cite web|title=Sulfadiazine|url=https://www.drugs.com/monograph/sulfadiazine.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161220223703/https://www.drugs.com/monograph/sulfadiazine.html|archivedate=20 December 2016|df=}}</ref>。因为磺胺嘧啶的血脑屏障透过率高，对治疗[[流行性脑炎|流行性脑炎]]特别有效<ref name=Zhu2012/>。临床上，有时会将磺胺嘧啶与[[乙胺嘧啶|乙胺嘧啶]]（Pyrimethamine）、[[叶酸|叶酸]]联用，治疗较严重的感染<ref name=Finch2010>{{cite book|author1=Roger G. Finch|author2=ETAL|title=Antibiotic and Chemotherapy|edition=9th edition|publisher=Elsevier|ISBN=978-0-7020-4064-1|year=2010}}</ref>{{rp|823-824}}。

== 参考文献 ==
{{Reflist|30em}}

{{-}}
{{核酸合成抑制剂类抗生素}}
{{国家基本药物目录/抗微生物药|nocat}}

[[Category:磺胺类抗菌药物|Category:磺胺类抗菌药物]]
[[Category:磺胺|Category:磺胺]]